

## Transcatheter Aortic Valve Replacement

Last Review Date: November 21, 2016

Number: MG.MM.SU.54c

### Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

### Definition

Transcatheter aortic valve replacement (TAVR), also known as transcatheter aortic valve implantation (TAVI) is a minimally invasive procedure for the treatment of aortic stenosis. A bioprosthetic valve is implanted percutaneously in the orifice of the native aortic valve. There are two access routes for TAVI—transfemoral and transapical (involving thoracotomy).

### Guideline

- A. Members are eligible for TAVR coverage when the method of insertion and clinical indication are commensurate with the FDA's approval of the device and when the following criteria are met:
  1. Severe native valve aortic stenosis or failure defined by  $\geq 1$  of the following:
    - a. Mean aortic valve gradient  $\geq 40$ mmHg
    - b. Peak jet velocity  $\geq 4.0$  m/s
    - c. Aortic valve area (AVA)  $< 0.8$  cm<sup>2</sup>
    - d. AVA Index  $< 0.6$  cm<sup>2</sup>/m<sup>2</sup>
  2. Presence of New York Heart Association (NYHA) symptoms  $\geq$  class II
  3. Inoperable or at high-risk for open heart surgery, as determined by two cardiovascular specialists (cardiologist and/or cardiac surgeon)

### Limitations/Exclusions

TAVR is not considered medically necessary for members with existing co-morbidities that would preclude the expected benefit from correction of the aortic stenosis.

Requests for TAVR as a repair to a previously implanted bio-prosthetic valve ("valve-in-valve"), which has degenerated, will be case-by-case reviewed.

## Revision History

11/21/2016 — removed provider and facility credentialing prerequisite.

## Applicable Procedure Codes

33361	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approach
33362	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery approach
33363	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approach
33364	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery approach
33365	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; transaortic approach (eg, median sternotomy, mediastinotomy)
33366	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; transapical exposure (eg, left thoracotomy) New code effective 1/1/2014
33367	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; cardiopulmonary bypass support with percutaneous peripheral arterial and venous cannulation (eg, femoral vessels) (List separately in addition to code for primary procedure)
33368	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; cardiopulmonary bypass support with open peripheral arterial and venous cannulation (eg, femoral, iliac, axillary vessels) (List separately in addition to code for primary procedure)
33369	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; cardiopulmonary bypass support with central arterial and venous cannulation (eg, aorta, right atrium, pulmonary artery) (List separately in addition to code for primary procedure)

## Applicable ICD-10 Diagnosis Codes

I06.0	Rheumatic aortic stenosis
I06.2	Rheumatic aortic stenosis with insufficiency
I06.8	Other rheumatic aortic valve diseases
I06.9	Rheumatic aortic valve disease, unspecified
I08.0	Rheumatic disorders of both mitral and aortic valves
I08.8	Other rheumatic multiple valve diseases
I08.9	Rheumatic multiple valve disease, unspecified
I35.0	Nonrheumatic aortic (valve) stenosis
I35.2	Nonrheumatic aortic (valve) stenosis with insufficiency
Q23.0	Congenital stenosis of aortic valve

## References

American College of Cardiology (ACC) Website. ACCF/AATS/SCAI/STS Expert Consensus Statement on Transcatheter Aortic Valve Replacement. <http://www.acc.org/search#q=consensus%20statement%20transcatheter&sort=relevancy> March 2012. Accessed October 28, 2016

American College of Cardiology (ACC) Website. AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. 2014. <http://content.onlinejacc.org/article.aspx?articleid=1838843>. Accessed October 28, 2016

CMS National Coverage Determination (NCD) for Transcatheter Aortic Valve Replacement (TAVR). January 2013. [http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=355&ncdver=1&NCAid=257&ver=4&NcaName=Transcatheter+Aortic+Valve+Replacement+\(TAVR\)&bc=ACAAAAACAAAAA%3D%3D&](http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=355&ncdver=1&NCAid=257&ver=4&NcaName=Transcatheter+Aortic+Valve+Replacement+(TAVR)&bc=ACAAAAACAAAAA%3D%3D&). Accessed October 28, 2016

Hayes, Winifred S. Directory Report. Transcatheter aortic valve implantation for aortic stenosis. October 2013; annual review April 2015. <http://www.hayesinc.com>. Accessed July 8, 2016.

Hayes, Winifred S. Search and Summary. Transapical aortic valve implantation using the Edwards Sapien transcatheter 9000 TFX heart valve and Ascendra balloon aortic valvuloplasty catheter. June 2014. <http://www.hayesinc.com>. Accessed July 8, 2016.

Sambu N, Curzen N. Transcatheter aortic valve implantation: The state of play. *Future Cardiol.* 2010;6(2):243-254.

Specialty matched clinical peer review.

US Food and Drug Administration (FDA) Website. FDA approves SAPIEN 3 THV artificial heart valve. June 2015. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm451678.htm>. Accessed October 28, 2016

US Food and Drug Administration (FDA) Website. Medtronic CoreValve System—P130021/S010. April 2015. <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma.cfm?num=p130021S010>. Accessed October 28, 2016

US Food and Drug Administration (FDA) Website. News Release. September 2013. FDA approval expands access to artificial heart valve for inoperable patients. <http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm369510.htm>. Accessed October 28, 2016

US Food and Drug Administration (FDA) Website. Edwards Sapien XT transcatheter heart valve. June 2014. <http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm405068.htm>. Accessed October 28, 2016

US Food and Drug Administration (FDA) Website. Medtronic CoreValve System — P130021. January 2014. <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma.cfm?num=p130021>. Accessed October 28, 2016